Alliance/NRG Joint Study: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, & Surgery (ERASur)
Principal Investigator
Kathryn Hitchcock, MD,
Status
Open to Accrual
Date Opened To Accrual
January 10 2023
Disease Site
Gastrointestinal [GI]
Colorectal
Phase
III
Developmental Therapeutics
No
Primary Objective
To evaluate and compare overall survival (OS) (measured from time of randomization) in patients with newly diagnosed oligometastatic colorectal cancer (oCRC) treated with total ablative therapy (TAT) in addition to standard of care (SOC) systemic therapy versus SOC systemic therapy.
Patient Population: Patients with metastatic colorectal cancer.
Alliance Study Chair: Eric D. Miller, MD, PhD
NRG Study Champions: Kate Hitchcock, MD & Paul Romesser, MD
Patient Population
Patients with metastatic colorectal cancer.
Target Accrual
364
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.